A late-stage trial of AstraZeneca’s oral prostate cancer drug zibotentan has been halted after it failed to meet its primary …
Danish biotech Bavarian Nordic is in ‘advanced discussions’ with a number of potential pharma partners for its phase II therapeutic …
AstraZeneca’s oncology pipeline has suffered a further blow after prostate cancer drug zibotentan failed to meet its primary endpoint of …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

